Prostate Cancer

>

Latest News

The phase 3 MIRAGE trial findings show that PROSTOX ultra was validated as a biomarker to predict genitourinary toxicity following SBRT.
PROSTOX ultra Reliably Predicts Long-Term Radiation AEs in Prostate Cancer

April 9th 2025

The phase 3 MIRAGE trial findings show that PROSTOX ultra was validated as a biomarker to predict genitourinary toxicity following SBRT.

Results from PSMAfore show that lutetium Lu 177 vipivotide tetraxetan elicited a median rPFS of 9.3 months vs 5.6 months with ARPI in prostate cancer.
FDA Approves Radioligand Therapy in PSMA–Positive, Castration-Resistant PC

March 28th 2025

Post-Radical Prostatectomy PSA Levels Reduced Overtreatment Risk After 3 Months
Post-Radical Prostatectomy PSA Levels Reduced Overtreatment Risk After 3 Months

March 26th 2025

The adverse effect profile was similar among patients with prostate cancer using NeuroSAFE-assisted RARP vs standard RARP.
NeuroSAFE Improves Erectile Function, Urinary Continence in Prostate Cancer

March 24th 2025

FDA Approves PET Imaging Agent for Prostate Cancer
FDA Approves PET Imaging Agent for Prostate Cancer

March 21st 2025

Latest CME Events & Activities

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

19th Annual New York GU Cancers Congress™

March 13-14, 2026

Register Now!

<1
...
6263646566